Moderate top-line growth assumptions are feasible for all traditional companies in the field of consumer healthcare.
Most of the multinational CHC companies are exhibiting low to medium single digit organic growth rates. Apparently shareholders can expect more. SME´s are performing superior growth despite limited resources. I am observing this phenomenon for many years with increasing interest.